Patients

1. Can the patient become pregnant after radionuclide therapy, or father a child?

After radionuclide therapy, a female patient should be advised to avoid pregnancy for the period of time indicated in the table. This is to ensure that the dose to a conceptus/foetus would probably not exceed 1 mGy (the member of the public dose limit). Potential spermatozoa damage in male patients is also allowed for in the case of iodine-131.

Suggested time period during which pregnancy should be avoided following radionuclide therapy

Radionuclide and form For treatment of All activities up to (MBq) Avoid pregnancy (months)
I-131 iodide Hyperthyroidism 800 4
I-131 iodide Thyroid cancer 6000 4
I-131 MIBG Neuroendocrine tumours 7500 3
P-32 phosphate Myeloproliferative 200 3
Sr-89 chloride Bone metastases 150 24
Y-90 colloid Radiation synovectomy 400 0
Y-90 colloid Malignancy 4000 1


Page Top

2. Can a patient breast feed a child after therapy?

Many radionuclides used in radiopharmaceuticals can appear in the breast milk of a nursing mother, which represents a potential radiation hazard to the newborn child. The principal risk to the child will be induction of cancer, and is considered to be a factor of two to three times higher than for the average population.

Many diagnostic radiopharmaceuticals clear rapidly from the body, and have radionuclides with a gamma emission only, and a short half-life. Therapy radionuclides, on the other hand, are designed to damage the target tissue, and often have particulate emissions (usually beta particles) and a longer half-life, in order to accomplish this aim.

Any therapeutic radiopharmaceutical administered orally, intravenously or arterially is potentially hazardous to the child, and breast feeding must cease. Intracavitary administrations of suspended particles such as yttrium-90 silicate represent little hazard; however, it would still be wise to cease feeding.

In particular, iodine-131 therapy is an absolute contra-indication to breast feeding.

Another contraindication to breast feeding after therapy is the necessary proximity of the child to the mother, which represents an external radiation hazard.

Page Top

3. What information should I get from the patient before administering the radiopharmaceutical?

Before treatment, the patient should be carefully identified, following normal hospital routine. The patient should also be interviewed in order not to forget important information necessary for safe treatment. The interview should include questions about pregnancy, breastfeeding, incontinence, nausea, type of work, use of public transport and living conditions. The information provided by the patient will determine how the therapy should be administered and what restrictions in the patient’s daily life are necessary in order to reduce the exposure of other people.

If it is anticipated that the patient will be unable to perform activities of daily living, will be confused, will become incontinent of urine, will have nausea or vomiting, or has other conditions which could complicate the course of post-treatment management, the nuclear medicine department and the RPO should inform and advise the patient. Laboratory procedures requiring urine or blood specimens should be performed before the treatment is administered.

Oral and written explanations of the therapy are useful to help the patient understand the nature of the treatment and any risks to the patient or other persons. It is the responsibility of the medical practitioner to perform this and to discuss it in detail with the patient. This procedure should also be recorded in the patient’s medical record. Examples of patient information sheets to be used in treatment with iodine-131 are given below.

Patient instruction card (pre-therapy)

I-131 THERAPY - WHAT’S IT ALL ABOUT ?

WHAT IS AN I-131 THERAPY DOSE FOR ?

!       I-131 therapy detects and treats any areas of residual thyroid tissue or tumour.

IS ANY PREPARATION REQUIRED?

!       For at least 1 month prior to I-131 therapy you must not have had iodine containing preparations (certain vitamin tablets, cough mixtures and kelp tablets) or X ray contrasts used for angiograms and CT scans.

!       Thyroid hormone medication will also need to be stopped for approximately 6 weeks before therapy. This will be arranged by your own doctor.

!       In addition, you require certain blood tests on the morning before I-131 administration (to check whether any residual thyroid tissue is adequately stimulated, and a pregnancy test if you are a woman of childbearing age). These tests will be organized by your own doctors.

!       The I-131 therapy dose is administered while you are in hospital. A hospital bed will be arranged for you.

VERY IMPORTANT

IF YOU ARE, OR COULD BE, PREGNANT OR ARE BREAST FEEDING, PLEASE NOTIFY STAFF BEFORE PROCEEDING WITH THE THERAPY DOSE. YOU MUST ALSO NOT BECOME PREGNANT FOR AT LEAST 6 MONTHS AFTER THE I131 THERAPY DOSE.

WHAT DOES AN I-131 THERAPY DOSE INVOLVE ?

! You will be admitted to a single room. A drug may be given to you prior to I-131 therapy to prevent potential nausea.

! A doctor and a technologist will come from the Department of Nuclear Medicine to administer the therapy dose. The doctor will check certain details (such as the date of surgery, and the result of any blood tests you may have had).

! You will then be asked to swallow a capsule containing the iodine-131. This radioisotope is accumulated by areas of thyroid tissue and destroys these areas.

 

!       The I-131 causes very few side effects. You may experience some minor neck discomfort over the first few days. No other discomfort is likely, though you need to remain in an isolation room for an average of four days.

!       The isolation room is used to limit radiation exposure to other people. You will be instructed about certain simple precautions to undertake.

!       The hospital's radiation safety officer will check your radioactivity level and will decide when you can be discharged home from hospital (usually three days after admission).

!       Before you are discharged, you will be brought to the Department of Nuclear Medicine where pictures of your body will be taken from various angles. Further delayed views may also be necessary.

!       When you are sent home, you will be instructed as to certain simple precautions to take over at least the next 7 days. Any additional precautions will be discussed with you.

1.    Avoid close or prolonged contact with pregnant women or very small children. A good guide is to stay more than one arm’s length away from people.

2.    Avoid unnecessary trips on public transport and attending public entertainment (you could be sitting next to someone pregnant).

3.    Flush toilet twice after use. Wash hands copiously.

4.    Do not attend work if this involves prolonged contact with people.

5.    If convenient, sleep in a single bed if partner is less than 50 years of age.

6.    Wash hands carefully before preparing food. Do not share your utensils with other family members and avoid activities which may involve exchange of saliva (e.g. kissing).

7.    If you are admitted to hospital within 4 weeks of the dose, please arrange for the Nuclear Medicine Department to be notified.

 


Patient instruction card (post-therapy)

The following is an example of an information card which should be given to the patient at the time of discharge, and which the patient should carry with them at all times for as long as the hospital has recommended (usually up to 4 weeks).

THIS CARD SHOULD BE CARRIED AT ALL TIMES UNTIL (date)

Patient name:

Address:

Treating hospital:

Hospital record number:

Treating doctor:

Radionuclide and form:

Activity:

Administered on (date):

In case of difficulty, please contact:

Telephone:                                     or the doctor named above.

 

Patient instructions :

  1. Avoid all close contact with children or pregnant women until (date).
  2. Avoid extended periods of close contact with children or pregnant women until (date).
  3. Avoid prolonged personal contact with adults at home until (date).
  4. Avoid prolonged close personal contact with adults away from home until (date).
  5. You may return to work on (date).
  6. Do not sleep with an adult in the same bed until (date).

 Signed:
(treating doctor)                                        

 Date:


Page Top

4. How do I know the absorbed dose given to the treated organ?

This information is not readily available for the individual patient. It can be reached only by careful calculations which are based on uptake measurements and other biokinetic data as well as on the mass of the treated tissue or organ. A rough estimate can be made using the MIRD or ICRP methods. According to the BSS, a medical physicist should be responsible for the clinical dosimetry.

Page Top

5. How do I know what activity to give when the referring physician has prescribed an absorbed dose to the thyroid?

By uptake measurements at different times after administration of a trace dose of iodine-131, the individual biokinetic data can be determined. The volume of the organ can be estimated by gamma camera or by other means like ultrasound examination. These measurements will provide enough information to calculate the activity to administer in order to reach a prescribed absorbed dose. Methods that simplify the procedure can be found in the literature.

Page Top

 
Copyright © 2009 International Atomic Energy Agency, Vienna International Centre, PO Box 100, 1400 Vienna, Austria